Literature DB >> 30651356

Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.

Bo Liang1, Barbora Kabatova2, Juraj Kabat3, David W Dorward4, Xiang Liu2, Sonja Surman2, Xueqiao Liu2, Annie Park Moseman2, Ursula J Buchholz2, Peter L Collins2, Shirin Munir2.   

Abstract

Human respiratory syncytial virus (RSV) is a major pediatric respiratory pathogen. The attachment (G) and fusion (F) glycoproteins are major neutralization and protective antigens. RSV G is expressed as membrane-anchored (mG) and -secreted (sG) forms, both containing a central fractalkine-like CX3C motif. The CX3C motif and sG are thought to interfere with host immune responses and have been suggested to be omitted from a vaccine. We used a chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) vector to express RSV wild-type (wt) G and modified forms, including sG alone, mG alone, mutants with ablated CX3C, and G with enhanced packaging into vector virions. In hamsters, these viruses replicated to similar titers. When assayed with a complement-enhanced neutralization assay in Vero cells, sG did not reduce the serum RSV- or PIV3-neutralizing antibody (NAb) responses, whereas ablating CX3C drastically reduced the RSV NAb response. Protective efficacy against RSV challenge was not reduced by sG but was strongly dependent on the CX3C motif. In ciliated human airway epithelial (HAE) cells, NAbs induced by wt G, but not by wt F, completely blocked RSV infection in the absence of added complement. This activity was dependent on the integrity of the CX3C motif. In hamsters, the rB/HPIV3 expressing wt G conferred better protection against RSV challenge than that expressing wt F. Codon optimization of the wt G further increased its immunogenicity and protective efficacy. This study showed that ablation of the CX3C motif or sG in an RSV vaccine, as has been suggested previously, would be ill advised.IMPORTANCE Human RSV is the leading viral cause of severe pediatric respiratory illness. An RSV vaccine is not yet available. The RSV attachment protein G is an important protective and neutralization antigen. G contains a conserved fractalkine-like CX3C motif and is expressed in mG and sG forms. sG and the CX3C motif are thought to interfere with host immune responses, but this remains poorly characterized. Here, we used an attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) vector to express various modified forms of RSV G. We demonstrated that strong antibody and protective responses could be induced by G alone, and that this was highly dependent on the integrity of the CX3C motif. There was no evidence that sG or the CX3C motif impaired immune responses against RSV G or the rB/HPIV3 vector. rB/HPIV3 expressing wt RSV G provides a bivalent vaccine against RSV and HPIV3.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  CX3C chemokine fractalkine; attachment protein; immune response; live vector vaccines; mucosal vaccines; neutralizing antibodies; parainfluenza virus; respiratory syncytial virus; viral glycoproteins

Mesh:

Substances:

Year:  2019        PMID: 30651356      PMCID: PMC6430528          DOI: 10.1128/JVI.02043-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.

Authors:  M N Teng; S S Whitehead; P L Collins
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

2.  The histopathology of fatal untreated human respiratory syncytial virus infection.

Authors:  Joyce E Johnson; Ricardo A Gonzales; Sandy J Olson; Peter F Wright; Barney S Graham
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

3.  An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Sean O Todd; Tatiana Chirkova; Thomas R Barnum; Kelsey A Gaston; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  Virology       Date:  2015-05-15       Impact factor: 3.616

Review 4.  Novel antigens for RSV vaccines.

Authors:  Barney S Graham; Kayvon Modjarrad; Jason S McLellan
Journal:  Curr Opin Immunol       Date:  2015-06-10       Impact factor: 7.486

5.  Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.

Authors:  Jennifer Harcourt; Rene Alvarez; Les P Jones; Christine Henderson; Larry J Anderson; Ralph A Tripp
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 6.  Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.

Authors:  B R Murphy; G A Prince; P L Collins; K Van Wyke Coelingh; R A Olmsted; M K Spriggs; R H Parrott; H W Kim; C D Brandt; R M Chanock
Journal:  Virus Res       Date:  1988-08       Impact factor: 3.303

7.  The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons.

Authors:  S R Roberts; D Lichtenstein; L A Ball; G W Wertz
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Role of complement in neutralization of respiratory syncytial virus.

Authors:  Sandra M Yoder; Yuwei Zhu; Mine R Ikizler; Peter F Wright
Journal:  J Med Virol       Date:  2004-04       Impact factor: 2.327

9.  The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.

Authors:  Alexander Bukreyev; Maria Elina Serra; Federico R Laham; Guillermina A Melendi; Steven R Kleeberger; Peter L Collins; Fernando P Polack
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.

Authors:  Hayat Caidi; Jennifer L Harcourt; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more
  8 in total

1.  Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.

Authors:  Kelsey A Brakel; Basavaraj Binjawadagi; Kristen French-Kim; Mauria Watts; Olivia Harder; Yuanmei Ma; Jianrong Li; Stefan Niewiesk
Journal:  Vaccine       Date:  2021-10-23       Impact factor: 3.641

2.  A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.

Authors:  Bo Liang; Yumiko Matsuoka; Cyril Le Nouën; Xueqiao Liu; Richard Herbert; Joanna Swerczek; Celia Santos; Monica Paneru; Peter L Collins; Ursula J Buchholz; Shirin Munir
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

3.  Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types.

Authors:  Lydia J Atherton; Patricia A Jorquera; Abhijeet A Bakre; Ralph A Tripp
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

4.  Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells.

Authors:  Binh Ha; Tatiana Chirkova; Marina S Boukhvalova; He Ying Sun; Edward E Walsh; Christopher S Anderson; Thomas J Mariani; Larry J Anderson
Journal:  Vaccines (Basel)       Date:  2019-07-19

5.  Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.

Authors:  Xueqiao Liu; Bo Liang; Xiang Liu; Emerito Amaro-Carambot; Sonja Surman; Peter D Kwong; Barney S Graham; Peter L Collins; Shirin Munir
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

6.  Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats.

Authors:  Margaret E Martinez; Cristina Capella Gonzalez; Devra Huey; Mark E Peeples; Douglas McCarty; Stefan Niewiesk
Journal:  PLoS One       Date:  2021-02-18       Impact factor: 3.240

Review 7.  Immunopathology of RSV: An Updated Review.

Authors:  Harrison C Bergeron; Ralph A Tripp
Journal:  Viruses       Date:  2021-12-10       Impact factor: 5.048

Review 8.  An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma.

Authors:  Sara Manti; Giovanni Piedimonte
Journal:  Front Pediatr       Date:  2022-09-20       Impact factor: 3.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.